March 22, 2024Cancer Research

Novel FcγR Humanized Mouse Model Enhances PK/PD Assessment of Therapeutic Antibodies

View Full Paper

Ask AI

Bookmark

Authors

FSFabiane SônegoGenoway (France)APAngela PappalardoGenoway (France)GMGaëlle MartinGenoway (France)

Discussion

Member takes

Implication

Randomized trial finds improved pharmacodynamics of therapeutic antibodies in humanized mice, suggesting better translatability to clinical applications.

Key Points

The humanized FcγR mouse model enables effective testing of therapeutic antibodies' pharmacokinetics and pharmacodynamics.
The study shows approximately 50% B-cell depletion in blood and liver after administration of human IgG1 targeting CD20.
Assessment utilized the novel model intercrossed with hSA/hFcRn to enhance translatability of antibody efficacy studies in human-like conditions, focusing on FcγR functionalities for ADCC analysis with Rituximab and Obinutuzumab toward tumor cells and influenza challenges. This model will also explore tolerability and biodistribution in future studies.

Cite This Study

Sônego et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce8b6db6435876a6ff2 https://doi.org/10.1158/1538-7445.am2024-5341

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds improved pharmacodynamics of therapeutic antibodies in humanized mice, suggesting better translatability to clinical applications.

Novel FcγR Humanized Mouse Model Enhances PK/PD Assessment of Therapeutic Antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

Novel FcγR Humanized Mouse Model Enhances PK/PD Assessment of Therapeutic Antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider